Search results
Results from the WOW.Com Content Network
Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo ...
(Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug ...
(Reuters) -Amgen will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
(Reuters) -Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering from a rare muscle-weakening disease, meeting the main goal of ...
Amgen, headquartered in California, is a publicly traded company and one of 30 in the Dow Jones Industrial, according to a state news release. It has more than 27,000 employees globally.
The U.S. Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics, while preventing the drugmaker from using anticompetitive tactics to ...
Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.CEO Bob Bradway shared a peek at phase II results of the ...